|Bid||0.5190 x 4000|
|Ask||0.5300 x 1200|
|Day's Range||0.5167 - 0.5700|
|52 Week Range||0.5167 - 3.0900|
|Beta (5Y Monthly)||6.60|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb. 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
IGC announced financial results for the quarter ended December 31, 2019, which is the third quarter of its 2020 fiscal year.
India Globalization Capital, Inc. (IGC) announces that its subsidiary Holi Hemp’s application has been approved and that it has executed agreements with operators to grow and harvest industrial hemp under the terms and conditions of the Industrial Hemp Program developed by the Arizona Department of Agriculture (AZDA). Our strategy is to ensure the highest quality output by controlling the production of important cannabinoids like Cannabidiol (CBD) and Cannabigerol (CBG) among others, both as a supplier and to support our products such as HyalolexTM and Holi HempTM. “We selected Arizona after much analysis including assessing climate, cost of labor, political environment, local support, logistics, market penetration, and competition, among other factors.
Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of India Globalization Capital, Inc. (IGC) has filed a derivative complaint against the company's officers and directors for breaches of fiduciary duty from October 25, 2017 through the present. India Globalization develops and commercializes cannabis-based therapies.
India Globalization Capital, Inc. (IGC) announces that it will host educational conferences in two of the largest cities in Puerto Rico on April 27, 2019 (San Juan) and April 28, 2019 (Ponce) from 9:00 a.m. to 5:00 p.m. each day. The Company previously hosted an educational conference on Saturday, March 30, 2019, in San Juan. This full-day event was similarly organized as a forum for distinguished speakers, including cannabis educators and a quality of life specialist, to address managing Alzheimer’s disease with Cannabinoids.
NEW YORK, April 2, 2019 /CNW/ -- In light of the rapid expansion of the cannabis market, many wonder what will be the next step for the industry. As of now, the cannabis market is heavily hindered by the lack of clinical trials and research, as most clinical trials conducted thus far have too few a number of participants, for government agencies such as the U.S. Food and Drug Administration, to approve. While the studies haven't led the FDA, or any other international health agencies, to approve the plant for medicinal uses, many countries have already moved to adopt medical cannabis legislation nonetheless.
India Globalization Capital, Inc. (IGC) announces today that, as of Wednesday, March 27, 2019, Hyalolex™, the Company’s cannabinoid-based, non-FDA approved product designed to assist in helping improve the lives of patients suffering from Alzheimer’s disease, will be available for purchase in select dispensaries in San Juan, Puerto Rico. The Company will host a doctor-patient education conference on Saturday, March 30, 2019, from 9:00 a.m. to 5:00 p.m., in San Juan, featuring several speakers. On January 24, 2019, the Company terminated its Licensing Agreement with DaMa Pharmaceutical, LLC, with a 90-day notice period, with the termination effective April 24, 2019, and the parties were unable to negotiate a replacement agreement.
HENDERSON, NV / ACCESSWIRE / March 12, 2019 / Year to date, the Global Cannabis Stock Index is up almost 50% in less than three months. It's safe to say investors are bullish on the cannabis. Here are ...
Global Consortium Inc (OTC:GCGX), India Globalization Capital Inc (NYSE American: IGC), Aphria Inc (NYSE: APHA, TSX: APHA), and Intellipharmaceutics International Inc (NASDAQ:IPCI) are 4 pot stocks worth looking into this week. Global Consortium Inc (OTC:GCGX) is a company that you might not have heard of but could benefit from checking out as we continue in this new year. Global Consortium Inc (OTC:GCGX) has made it a point to build a corporate framework to support its endeavors, recent of which have included building a "Cannabis Mall." According to reports, the project, once completed, will house manufacturing, distribution, delivery, retail, testing, and cultivation all under one 64,000 sq. ft building.